Brief: Basilea: Two New Preclinical Collaborations To Develop Novel Antibacterial And Antifungal Drugs

Basilea Pharmaceutica AG, Allschwil

08/01/2026 06:18

Jan 8 (Reuters) - BASILEA PHARMACEUTICA AG ALLSCHWIL BSLN.S:

PROVIDES PORTFOLIO UPDATE AND OUTLOOK

TWO NEW PRECLINICAL COLLABORATIONS TO DEVELOP NOVEL ANTIBACTERIAL AND ANTIFUNGAL DRUGS

FOSMANOGEPIX SECOND PHASE 3 STUDY INITIATED; TWO PHASE 3 STUDIES IN INVASIVE FUNGAL INFECTIONS PROGRESSING AS PLANNED

CLINICAL PORTFOLIO STRENGTHENED THROUGH IN-LICENSING OF PHASE 3-READY ANTIBIOTIC CEFTIBUTEN-LEDABORBACTAM

PARTNERS WITH PHARE BIO TO USE AI IN ANTIBIOTIC DISCOVERY

Source text: ID:nGNE72xJwV

Further company coverage: BSLN.S

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))